HIGHLIGHTS
- who: ABT and colleagues from the DepartmentUniversity of Missouri, Columbia, Missouri, USA have published the Article: SMARD1 pathology via interactions with IGHMBP2, in the Journal: (JOURNAL) of September/26,/2022
- what: This study examines activator of basal transcription 1 (ABT1) a modifier of SMARD1-nmd disease pathology. The authors provide a mechanism proposing that decreases disease pathology in FVB-Ighmbp2nmd/nmd mutants by optimizing IGHMBP2 biochemical activity (ATPase and helicase activity). The studies provide insight into SMARD1 pathogenesis suggesting that modifies IGHMBP2 activity as a means to regulate pre-rRNA processing. Toward this end, the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.